<DOC>
	<DOCNO>NCT00614978</DOCNO>
	<brief_summary>Objectives : Primary - Determine maximum tolerate dose ( MTD ) evaluate dose limit toxicity ( DLT ) combine lapatinib temozolomideSecondary - Obtain preliminary information clinical anti-tumor activity lapatinib plus temozolomide brain metastasis secondary HER-2 positive breast cancer include Objective Response Rate ( ORR ) , Clinical Benefit ( CB ) Duration Response ( DR ) Methodology : Phase I , single-centre , open-label , dose-escalation study combine lapatinib temozolomide HER-2 positive breast cancer patient progressive brain metastasis surgery radiotherapy radiosurgery Treatment : Temozolomide give orally 5 day every 28 day , dose either 100mg/m2/day 150mg/m2/day 200mg/m2/day AND Lapatinib give orally every day either 1000mg/day 1250mg/day 1500mg/day.Sequential cohort escalate increment accord dose escalation scheme , determine dose limit toxicity .</brief_summary>
	<brief_title>Lapatinib Temozolomide Treatment Progressive Brain Disease HER-2 Positive Breast Cancer</brief_title>
	<detailed_description>Patients selection criterion : - age 18 - 70 year - Women cytologically histologically proven metastatic breast cancer recurrent / progressive brain metastasis evaluable MRI , standard treatment surgery ( least 3 week prior ) WBRT ( least 3 week prior ) stereotactic RT ( least 1 week prior ) ; otherwise deem unsuitable standard treatment first instance - Known HER-2 positive status ( immunohistochemistry ( IHC ) 3+ Fluorescence In Situ Hybridization ( FISH ) positive ) - Previous chemotherapy ( adjuvant metastatic regimen ) allow - Previous treatment trastuzumab allow ( Trastuzumab discontinue prior study entry ) - At least one measurable lesion brain , defined lesion &gt; 5mm long dimension T1-weighted , gadolinium-enhanced MRI - Expected life-expectancy 3 month - ECOG performance status 0 , 1 2 - Adequate bone marrow , renal hepatic functionsLVEF - LVEF 50 % measure echocardiography MUGA scan - Concomitant corticosteroid anti-convulsants symptomatic brain metastasis allow</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>18 70 year Women cytologically histologically proven metastatic breast cancer recurrent / progressive brain metastasis evaluable MRI , standard treatment surgery ( least 3 week prior ) WBRT ( least 3 week prior ) stereotactic RT ( least 1 week prior ) ; otherwise deem unsuitable standard treatment first instance Known HER2 positive status ( immunohistochemistry ( IHC ) 3+ Fluorescence In Situ Hybridization ( FISH ) positive ) Previous chemotherapy ( adjuvant metastatic regimen ) allow Previous treatment trastuzumab allow ( Trastuzumab discontinue prior study entry ) At least one measurable lesion brain , defined lesion &gt; 5mm long dimension T1weighted , gadoliniumenhanced MRI Expected lifeexpectancy 3 month ECOG performance status 0 , 1 2 Adequate bone marrow , renal hepatic functionsLVEF LVEF &gt; 50 % measure echocardiography MUGA scan Concomitant corticosteroid anticonvulsant symptomatic brain metastasis allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>HER-2 positive ; brain metastasis</keyword>
</DOC>